Biosimilars: complements and comments on the recent statement of the SFR and CRI. Comment on: “Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).” Schaeverbeke et al. Joint Bone Spine 2018;95:399-402 - 04/12/18

Jean-David Cohen ^{a, ⁎} , Sonia Tropé ^b, Audrey Munos ^c, François Bocquet ^{d, e, f}

^a Rheumatology department, Lapeyronie hospital, Montpellier university hospital center, 34295 Montpellier Cedex 5, France 

^b French national patient organization against rheumatoid arthritis (ANDAR), 75014 Paris, France 

^c BioCube institute, groupe IMT, 37000 Tours, France 

^d Law and health economics department, faculty of pharmacy, Paris Descartes university, Sorbonne Paris Cité, 4, avenue de l’Observatoire, 75006 Paris, France 

^e Health law institute (Inserm UMR S1145), Paris Descartes university, Sorbonne Paris Cité, 45, rue des Saints-Pères, 75006 Paris, France 

^f Pharmacy department, general agency of equipments and health products (AGEPS), 7, rue du Fer à Moulin, 75005 Paris, France 

^⁎Corresponding author at : Département de rhumatologie, 371, avenue du Doyen-Gaston Giraud, 34295 Montpellier Cedex 5, France.Département de rhumatologie371, avenue du Doyen-Gaston GiraudMontpellier Cedex 534295France

Le texte complet de cet article est disponible en PDF.